(Q38007115)

English

Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials

scientific article published on 02 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

inflammatory bowel diseases

0 references

0 references

Crohn's disease

0 references

systematic review

1 reference

based on heuristic

inferred from title

author name string

Lee Roth

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

John K MacDonald

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

John W D McDonald

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Nilesh Chande

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

2 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Inflammatory Bowel Diseases

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1333-1339

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Sargramostim for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Adding fuel to the fire: GM-CSF for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Sargramostim in patients with Crohn's disease: results of a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Identifiers

10.1002/IBD.22973

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38007115&oldid=1736990033"